Roche's Tecentriq combination to get speedy FDA review

ZURICH (Reuters) - Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get a speeded-up review by U.S. regulators for use in initial treatment of people with a common form of lung cancer, the Swiss drugmaker said on Monday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news